ChemoCentryx's stock jumps 80% after receiving FDA approval for vasculitis drug

2 years ago 201

Published: Oct. 8, 2021 astatine 8:24 a.m. ET

Shares of ChemoCentryx Inc. soared 80.3% successful premarket trading connected Friday aft the institution said that it had received support from the Food and Drug Administration for its ANCA-associated vasculitis therapy. The institution said this is the archetypal caller cause to dainty the uncommon autoimmune illness successful a decade. ChemoCentryx's banal slipped 68.3% this year, portion the broader S&P 500 is up 16.1%.

...

Read Entire Article

ChemoCentryx's stock jumps 80% after receiving FDA approval for vasculitis drug

Related

Guest Posting to Establish Thought Leadership in Your Indust...

Strong Insider Buying Could Indicate a Bottom in These 3 Sto...

Cathie Wood’s ARK ETFs Are in a Deep Hole—Already

Interest-Rate Worries Batter Stock Market

Trending

Popular

Akamai adds new capabilities and tools for developers

Muḥammad ibn Mūsā al-Khwārizmī

Non-IT pros will build the bulk of tech products and service...

SEC Delays Review of Kryptoin’s Bitcoin ETF Application

⚠️ Warning: Major Traffic Shift Coming For I-395 Ramp To I-9...